ICOTYDE™
(icotrokinra) tablets

ICOTYDE: THE INNOVATIVE SCIENCE BEHIND TARGETED ORAL PEPTIDES

in Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23 receptor–targeted oral peptide in a once-daily pill for moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg.

PROGRAM OBJECTIVES

1. Review unmet need in psoriasis
2. Introduce ICOTYDE mechanism of action
3. Discuss key safety and efficacy results from the ICONIC clinical trial program

PLEASE JOIN THIS PROMOTIONAL SPEAKER PROGRAM | A LIVE PROGRAM

DATE

Thursday November 19, 2026
6:00 PM ET Arrival
6:30 PM ET Dinner & Presentation

LOCATION

Gourmet and Company
214 E Mountcastle Dr
Johnson City TN 37601
(423) 929-9007

PRESENTED BY

Laura Bush, PA-C
Physician Assistant
Fayette Area Dermatology
Fayetteville, GA

REGISTRATION

JOIN US by registering at
MyDomeProgramRegistration.com
and enter meeting code: 2026-10190

Data rates may apply.

Please note that your e-mail will be required for registration. The information you provide will only be used to facilitate your attendance at this program. If you have questions about this program, please contact your Johnson & Johnson representative. We look forward to your participation in this informative discussion. Sponsored by Johnson & Johnson.

Speakers are being compensated by Johnson & Johnson for participation in this program.

INDICATION

ICOTYDE™ (icotrokinra) 200 mg is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.

DOSAGE AND ADMINISTRATION

The recommended dosage of ICOTYDE for adults and pediatric patients (12 years of age and older who weigh at least 40 kg) is 200 mg taken orally once daily. Take ICOTYDE upon waking on an empty stomach with water. After taking ICOTYDE, wait at least 30 minutes before eating food.

SELECTED IMPORTANT SAFETY INFORMATION

Avoid treatment with ICOTYDE™ in patients with any clinically important active infection until the infection resolves or is adequately treated. If such an infection develops, discontinue ICOTYDE until the infection resolves. Consider evaluating for tuberculosis (TB) prior to initiating treatment with ICOTYDE based on clinical judgement. Monitor patients for signs and symptoms of active TB during and after treatment. Avoid use of live vaccines during treatment. Please see related and other Important Safety Information on following page.

ICOTYDE™
(icotrokinra) tablets

Johnson&Johnson

© Johnson & Johnson and its affiliates 2026 03/26 cp-572685v1

ICOTYDE™
(icotrokinra) tablets

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infections

Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ICOTYDE. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection and/or is not responding to standard therapy, monitor the patient closely and discontinue ICOTYDE until the infection resolves.

Tuberculosis (TB)

Consider evaluating for TB prior to initiating treatment with ICOTYDE based on clinical judgement. Consider anti-TB therapy prior to initiating ICOTYDE in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment. Avoid administering ICOTYDE to patients with active TB.

Immunizations

Avoid use of live vaccines in patients during treatment with ICOTYDE. Medications that interact with the immune system may increase the risk of the infection following administration of live vaccines. Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.

ADVERSE REACTIONS

Most common adverse reactions (≥1%) are headache, nausea, cough, fungal infection, and fatigue. The adverse reactions observed in pediatric patients were consistent with the most common adverse reactions (≥1%) observed in the overall population.

USE IN SPECIFIC POPULATIONS

Moderate or Severe Renal Impairment

Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min.

Pregnancy

The available data on the use of ICOTYDE during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Please read the full Prescribing Information and Medication Guide for ICOTYDE.

Provide the Medication Guide to your patients and encourage discussion.

cp-564098v1

DISCLOSURE

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

Johnson&Johnson

© Johnson & Johnson and its affiliates 2026 03/26 cp-572685v1